Enrico Martin

131 Diagnostic accuracy of non-invasive tests References 1. Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg . 2005;102:246–255. 2. Montano N, D’Alessandris QG, D’Ercole M, et al. Tumors of the peripheral nervous system: Analysis of prognostic factors in a series with long-term follow-up and review of the literature. J Neurosurg . 2016;125:363–371. 3. Le Guellec S, Decouvelaere A-V, Filleron T, et al. Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Patholog y Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database. Am J Surg Pathol . 2016;40:896–908. 4. Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg . 2014;260:412–416. 5. Evans DGR, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet . 2002;39:311–314. 6. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet . 2007;44:81–88. 7. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77–84. 8. Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer . 2019;124:77–87. 9. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19:878–885. 10. Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg . 2013;118:142–148. 11. Nelson CN, Dombi E, Rosenblum JS, et al. Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg . 2019;1–11. 12. Hajiabadi MM, Campos B, Sedlaczek O, et al. Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. Langenbeck’s Arch Surg . . Epub ahead of print January 2020. DOI: 10.1007/s00423-019-01851-5. 13. Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral ner ve sheath tumors and neurofibromas. Am J Roentgenol . 2010;194:1568–1574. 14. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet . 2007;15:131–138. 15. Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med . 2013;38:e19-25. 16. Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging . 2019;46:776–787. 17. Perez-Roman RJ, Shelby Burks S, Debs L, et al. The Risk of Peripheral Nerve Tumor Biopsy in Suspected Benign Etiologies. Neurosurgery . . Epub ahead of print January 2020. DOI: 10.1093/neuros/ nyz549. 18. Graham DS, Russell TA, Eckardt MA, et al. Oncologic Accuracy of Image-guided Percutaneous Core-Needle Biopsy of Peripheral Nerve Sheath Tumors at a High-volume Sarcoma Center. Am J Clin Oncol . 2019;42:739–743. 6